Revenue from Contracts with Customers

12 Months Ended

Dec. 31, 2021

Revenue from Contract with Customer [Abstract]

Revenue from Contracts with Customers

Note 5 - Revenue from Contracts with Customers

Disaggregated Revenue

The Company provides diagnostic test products, laboratory services to hospitals, clinical laboratories and other healthcare provider customers, and enters into collaboration agreements with government agencies and healthcare providers. The revenues by type of service consist of the following:

	Years Ended December,
	2021		2020
Product sales	$	2,656,669	$	2,704,364
Laboratory services		813,210		167,736
Collaboration revenue		836,152		1,342,341
Total revenue	$	4,306,031	$	4,214,441

Revenues by geography are as follows:

	Years Ended December,
	2021		2020
Domestic	$	1,203,748	$	1,917,367
International		3,102,283		2,297,074
Total revenue	$	4,306,031	$	4,214,441

F-20

Deferred revenue

Changes in deferred revenue for the period were as follows:

Balance at December 31, 2019	$	9,808
Acquired deferrals from Curetis		829,275
Revenue recognized in the period from amounts acquired from Curetis		(870,114	)
Effect of foreign exchange rates		40,839
Balance at December 31, 2020		9,808
New deferrals, net of amounts recognized in the current period		—
Amounts returned to customers		(9,808	)
Effect of foreign exchange rates		—
Balance at December 31, 2021	$	—

Contract assets

The Company had approximately $0 and $18,000 of contract assets as of December 31, 2021 and 2020 respectively, which are generated when contractual billing schedules differ from revenue recognition timing. Contract assets represent a conditional right to consideration for satisfied performance obligations that becomes a billed receivable when the conditions are satisfied.

Unsatisfied performance obligations

The Company had no unsatisfied performance obligations related to its contracts with customers at December 31, 2021 and 2020.